Loxo Oncology price target raised to $202 from $122 at Oppenheimer. Oppenheimer analyst Leah Rush Cann raised her price target for Loxo Oncology to $202 from $122 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.